Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07815873 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers

Name: Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers — clinical trial record (NCT07815873)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CERBERO

StatusNot Yet Recruiting

PhaseNot applicable

SponsorEuropean Institute of Oncology

Started2026-10-01

View on ClinicalTrials.gov ↗

This study aims to investigate the role of the gut microbiota and its derived factors, including bacterial-associated antigens that mimic tumor-associated antigens, in predicting response to immune checkpoint inhibitor immunotherapies in patients with various types of cancer. The aim is to explore whether gut microbiota-mediated immunological modulation is specific to the tumor being treated and whether it can be used to enhance antitumor response.

Trial Details

NCT Number	NCT07815873
Lead Sponsor	European Institute of Oncology
Conditions	Non Small Cell Lung Cancer, Melanoma (Skin Cancer), Endometrial Cancer, Cervical Cancer
Enrollment	360 participants
Start Date	2026-10-01
Primary Completion	2027-10-01 (estimated)
Study Completion	2031-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-09-11